Literature DB >> 34370147

Synergistic effects of Rapamycin and Fluorouracil to treat a gastric tumor in a PTEN conditional deletion mouse model.

Cong-Hui Zhu1,2, Shuang-Qing Peng1, Li-Li Cui3, Wanying Cao4, Li-Shi Zhang2, Zeng-Ming Zhao1, Li Jia1, Ting-Fen Zhang1, Jia-Bin Guo1, Chengfang Pang5.   

Abstract

The tumor suppressor gene phosphatase and tensin homolog (PTEN) in PI3K/Akt/mTOR pathway is essential in inhibiting tumor growth and metastasis. However, whether the mutation of PTEN gene could induce tumorigenesis and impact the treatment of gastric cancer is still unclear. The purpose of the study was to investigate the combined treatment of gastric tumorigenesis using Rapamycin and Fluorouracil (5-Fu) through interfering with the Akt/mTOR pathway in a mouse model with PTEN conditional deletion. Three groups of mice were exposed for 5 days to Rapamycin and 5-Fu separately and together. The gene expression of the Akt/mTOR pathway, the protein expression of caspase-3 and p-Akt, p-S6K and p-4EBP1, and the pathological changes in stomachs were analyzed. Our study demonstrates that the conditional PTEN deletion in the cells of glandular stomach induces hyperplastic gastric tumors in mice. The combined Rapamycin administration with 5-Fu resulted in better outcomes than their separate administration for the treatment of gastric cancer by inhibiting the mTOR signal pathway. Our study indicates that Rapamycin has a synergistic interaction with chemotherapeutic 5-Fu, and demonstrates a potential therapeutic combination treatment on glandular stomach tumor with PTEN functional absence or aberrantly activated Akt/mTOR pathway. It provides important insights into the inhibition of the Akt/mTOR pathway in gastric cancer clinical therapy.
© 2021. The International Gastric Cancer Association and The Japanese Gastric Cancer Association.

Entities:  

Keywords:  5-Fluorouracil; Akt/mTOR; Gastric tumorigenesis; PTEN; Rapamycin

Mesh:

Substances:

Year:  2021        PMID: 34370147     DOI: 10.1007/s10120-021-01229-x

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  39 in total

Review 1.  The impact of a negligent G2/M checkpoint on genomic instability and cancer induction.

Authors:  Markus Löbrich; Penny A Jeggo
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

Review 2.  G protein regulation of MAPK networks.

Authors:  Z G Goldsmith; D N Dhanasekaran
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

3.  Caspase activation cascades in apoptosis.

Authors:  Susan E Logue; Seamus J Martin
Journal:  Biochem Soc Trans       Date:  2008-02       Impact factor: 5.407

4.  Trend in gastric cancer: 35 years of surgical experience in Japan.

Authors:  Keishi Yamashita; Shinichi Sakuramoto; Masayuki Nemoto; Tomotaka Shibata; Hiroaki Mieno; Natsuya Katada; Shiroh Kikuchi; Masahiko Watanabe
Journal:  World J Gastroenterol       Date:  2011-08-07       Impact factor: 5.742

5.  Prognostic analysis of familial gastric cancer in Chinese population.

Authors:  Yan-Wei Ye; Rui-Zheng Dong; Ye Zhou; Chun-Yan Du; Chun-Meng Wang; Hong Fu; Ying-Qiang Shi
Journal:  J Surg Oncol       Date:  2011-03-11       Impact factor: 3.454

6.  PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Authors:  Hongbing Zhang; Natalia Bajraszewski; Erxi Wu; Hongwei Wang; Annie P Moseman; Sandra L Dabora; James D Griffin; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2007-02-08       Impact factor: 14.808

Review 7.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.

Authors:  Franck Toledo; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

Review 8.  Integrating signals from RTKs to ERK/MAPK.

Authors:  M M McKay; D K Morrison
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 9.  The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.

Authors:  Yoko Aoki; Tetsuya Niihori; Yoko Narumi; Shigeo Kure; Yoichi Matsubara
Journal:  Hum Mutat       Date:  2008-08       Impact factor: 4.878

Review 10.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.